Skip to Content

New Additions to for 2017

We update the database on a regular cycle. The following new drug information has been added this year:

Showing additions for:

Apr 12, 2017 - Ingrezza (valbenazine) is a novel, highly-selective VMAT2 inhibitor for the treatment of tardive dyskinesia.

Apr 3, 2017 - Austedo (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.

Mar 29, 2017 - Ocrevus (ocrelizumab) is a humanized monoclonal antibody designed to selectively target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin and axonal nerve cell damage. Ocrevus is indicated as a treatment for both relapsing (RMS) and primary progressive (PPMS) forms of multiple sclerosis.

Mar 28, 2017 - Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis.

Mar 28, 2017 - Zejula (niraparib) is an oral, poly ADP-ribose polymerase (PARP) inhibitor for the treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

Mar 28, 2017 - Symproic (naldemedine) is a peripherally-acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation.

Mar 24, 2017 - Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of patients with metastatic Merkel cell carcinoma (MCC).

Mar 22, 2017 - Xadago (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.

Mar 13, 2017 - Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor indicated for the treatment of postmenopausal women with HR+/HER2- metastatic breast cancer.

Mar 2, 2017 - Siliq (brodalumab) is a human anti-interleukin-17-receptor monoclonal antibody for the treatment of plaque psoriasis.

Feb 28, 2017 - Qtern (dapagliflozin and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP4) inhibitor fixed-dose combination for the treatment of adult patients with type 2 diabetes.

Jan 25, 2017 - Trulance (plecanatide) is a uroguanylin analog for the treatment of chronic idiopathic constipation.

Jan 23, 2017 - Rhofade (oxymetazoline hydrochloride) cream is a topical vasoconstrictor for the treatment of facial erythema associated with rosacea.

Browse additions by year: